David Sourdive

Co-Founder & EVP CMC Manufacturing • Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000.
Dr. Sourdive combines a strong scientific expertise with experience in managing industrial
programs bringing innovative technologies to industrial fruition. He served as Executive Vice
President, Corporate Development, from 2008 to 2016 and as Executive Vice President,
Technical Operations until July 2019. In addition to his role at Cellectis, Dr. Sourdive has also
served on the board of directors of the Mediterranean Institute for Life Sciences. David
Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology
at Institut Pasteur and completed a research fellowship in the Emory University Department
of Microbiology and Immunology. His management training is from the HEC (Challenge +) and
his decade-long experience in industrial program management was acquired at the
French Department of Defense (DGA) prior to Cellectis’ inception.

Also speaking

Sofia Hakansson Buch

Vice President for Cell Therapy CMC • Novo Nordisk

Qasim Rafiq

Associate Professor Cell & Gene Therapy • UCL

Ann-Hunter Van Kirk

Senior Equity Research Analyst Biopharmaceuticals • Bloomberg Intelligence

Event Info


Sponsorship Brochure

Take a look at the 2023 sponsorship opportunities here.

Agenda at a Glance

Check out the Agenda at a Glance for Advanced Therapies Europe 2023.